New Patent Expands Geographic Coverage
IRVING, Texas, Feb. 11 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that the Eurasian Patent Office has granted patent application No. 200600484, titled "Delivery of Physiological Agents with In-Situ Gels Comprising Anionic Polysaccharides," relating to the Company's proprietary GelSite(R) polymer technology. DelSite Biotechnologies, Inc., Carrington's wholly owned subsidiary, is developing and commercializing GelSite(R) polymer as a controlled-release drug delivery technology for pharmaceutical and vaccine products.
The Eurasian Patent Office, located in Moscow, represents nine Eurasian countries with a combined population of more than 200 million people. The countries in the region include: Turkmenistan, the Republic of Belarus, the Republic of Tajikistan, the Russian Federation, the Azerbaijan Republic, the Republic of Kazakhstan, the Kirghiz Republic (Kyrgyzstan), the Republic of Armenia, and the Republic of Moldova.
The patent specifically covers the in-situ gelation (gelling in place) powder technology based on GelSite(R) polymer. GelVac(TM), the Company's nasal powder platform developed based on this technology, is being developed for nasal delivery of vaccines and therapeutics. The GelVac(TM) platform holds distinct advantages over traditional drug delivery methods, including room temperature stability, no requirement for cold storage and distribution, no need for preservatives, and self-administration. The Company's lead product candidate, GelVac(TM) nasal powder vaccine for influenza H5N1 (avian flu), has passed animal toxicology studies and a Phase I clinical study is planned for 2008.
"This patent reflects our desire to protect intellectual properties in
all the countries where we believe DelSite's delivery system will provide
competitive advantages," said Carlton E. Turner, PhD, CEO of Carrington.
|SOURCE Carrington Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved